Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Penel

Showing results (21-30 of 350) with videos related to

Pageof 35
Sort By:
Bulletin Du Cancer|March 18, 2020
[Desmoid type fibromatosis, from radical excision to molecular extirpation]Nicolas Penel, Daniel Orbach
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2015
Reply to B. Biswas and D. DabkaraNicolas Penel, Isabelle Ray-Coquard
Bulletin Du Cancer|February 22, 2022
[Cancer research: France facing geopolitical changes and territorial inequality]Nicolas Penel, Jacques-Olivier Bay
Bulletin Du Cancer|April 21, 2019
[Cancer screening words]Simone Mathoulin-Pélissier, Nicolas Penel
Palliative & Supportive Care|June 23, 2009
When cancerophobia and denial lead to deathMichel Reich, Cecile Gaudron, Nicolas Penel
Current Opinion in Oncology|May 11, 2017
Adult desmoid tumors: biology, management and ongoing trialsNicolas Penel, Frédéric Chibon, Sébastien Salas
Investigational New Drugs|February 2, 2010
Proposal for size justification of expanded cohort at phase-2-recommended doseNicolas Penel, Charles Fournier, Jocelyne Bérille
Bulletin Du Cancer|December 9, 2019
[Systemic treatment for management of aggressive fibromatosis in both adult and children: Level of evidence and unsolved questions]Nicolas Penel, Thomas Ryckewaert, Daniel Orbach
Investigational New Drugs|May 9, 2009
Phase II trials in patients with carcinoma of unknown primary: a pooled data analysisAntoine Adenis, Charles Ferté, Nicolas Penel
Bulletin Du Cancer|May 6, 2014
What is an active regimen in carcinoma of unknown primary sites? Analysis of correlation between activity endpoints reported in phase II trials. Correlation of activity endpoints in phase II trialsNicolas Penel, Thomas Ryckewaert, Andrew Kramar
Pageof 35

Showing results (21-30 of 350) with videos related to

Sort By:
Pageof 35
Bulletin Du Cancer|March 18, 2020
[Desmoid type fibromatosis, from radical excision to molecular extirpation]Nicolas Penel, Daniel Orbach
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2015
Reply to B. Biswas and D. DabkaraNicolas Penel, Isabelle Ray-Coquard
Bulletin Du Cancer|February 22, 2022
[Cancer research: France facing geopolitical changes and territorial inequality]Nicolas Penel, Jacques-Olivier Bay
Bulletin Du Cancer|April 21, 2019
[Cancer screening words]Simone Mathoulin-Pélissier, Nicolas Penel
Palliative & Supportive Care|June 23, 2009
When cancerophobia and denial lead to deathMichel Reich, Cecile Gaudron, Nicolas Penel
Current Opinion in Oncology|May 11, 2017
Adult desmoid tumors: biology, management and ongoing trialsNicolas Penel, Frédéric Chibon, Sébastien Salas
Investigational New Drugs|February 2, 2010
Proposal for size justification of expanded cohort at phase-2-recommended doseNicolas Penel, Charles Fournier, Jocelyne Bérille
Bulletin Du Cancer|December 9, 2019
[Systemic treatment for management of aggressive fibromatosis in both adult and children: Level of evidence and unsolved questions]Nicolas Penel, Thomas Ryckewaert, Daniel Orbach
Investigational New Drugs|May 9, 2009
Phase II trials in patients with carcinoma of unknown primary: a pooled data analysisAntoine Adenis, Charles Ferté, Nicolas Penel
Bulletin Du Cancer|May 6, 2014
What is an active regimen in carcinoma of unknown primary sites? Analysis of correlation between activity endpoints reported in phase II trials. Correlation of activity endpoints in phase II trialsNicolas Penel, Thomas Ryckewaert, Andrew Kramar
Pageof 35